Literature DB >> 9659534

Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease.

D Dev1, E Wallace, R Sankaran, J Cunniffe, J R Govan, C G Wathen, F X Emmanuel.   

Abstract

C-reactive protein (CRP) has been shown to be a useful and sensitive indicator of pyogenic infections in many clinical situations, including acute pneumonia and infective pulmonary exacerbations in cystic fibrosis patients. Exacerbations of COPD are often, but not always, associated with demonstrable infection. The value of CRP measurement in this situation has not been assessed. We have evaluated CRP measurement in 50 patients [age 71 +/- 8 (SD) years] who were admitted to hospital with clinical evidence of exacerbation [PaO2 = 7.3 +/- 1.3 (SD) kPa, baseline FEV1 = 0.8 +/- 0.4 (SD) l]. These patients all had serial measurement of CRP [polarizing immunofluorescence (Abbot, TDx)], peripheral white cell count (WCC), body temperature, peak expiratory flow rate, Karnofsky performance status and chest X-ray, in addition to serial sputum bacteriological analysis carried out in a specialized laboratory. CRP was elevated (> 10 mg l-1) in all patients (n = 29) with proven infection [103 +/- 98 (SD) mg l-1]. Levels were markedly elevated in patients infected with Streptococcus pneumoniae (mean 156 mg l-1); there was also a rapid fall in the CRP with therapy. WCC fell with therapy, giving a correlation with CRP level (r = 0.44, P < 0.01). Since CRP elevation was observed in patients having exacerbation with proven infections and also in those where infection was not proven, it is possible that, while it is a marker for COPD exacerbation, it is not necessarily a marker of bacterial infection per se. However, it is evident from our study that it is of value in the assessment of exacerbations of COPD, where routine bacterial culture of sputum is often unreliable, and thus the measurement of serum CRP may provide an additional objective indicator of infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9659534     DOI: 10.1016/s0954-6111(98)90515-7

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  26 in total

Review 1.  Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Omar A Minai; Zab Mosenifar
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

2.  Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD.

Authors:  Hakan Tanrıverdi; Tacettin Örnek; Fatma Erboy; Bülent Altınsoy; Fırat Uygur; Figen Atalay; Müge Meltem Tor
Journal:  Wien Klin Wochenschr       Date:  2015-01-14       Impact factor: 1.704

3.  Blood biomarkers as predictors of long-term mortality in COPD.

Authors:  Angelico Mendy; Erick Forno; Theophile Niyonsenga; Janvier Gasana
Journal:  Clin Respir J       Date:  2018-01-05       Impact factor: 2.570

4.  Raised CRP levels mark metabolic and functional impairment in advanced COPD.

Authors:  R Broekhuizen; E F M Wouters; E C Creutzberg; A M W J Schols
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

5.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 6.  Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease.

Authors:  Neil MacIntyre; Yuh Chin Huang
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 7.  Cardiac disease in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Steven Kadiev; Gerard J Criner; Steven M Scharf; Omar A Minai; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 8.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12

9.  Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I.

Authors:  M A Spruit; R Gosselink; T Troosters; A Kasran; G Gayan-Ramirez; P Bogaerts; R Bouillon; M Decramer
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.